With a median survival of about two years, the prognosis for metastatic colorectal cancer remains poor. New therapeutic options have brought some improvement in recent years, but major breakthroughs have been lacking. This year’s ASCO Annual Meeting was again all about the details. And yet, some exciting insights into optimizing first-line therapy were presented.